Introduction:
Vandria SA, a Lausanne-based company, has raised CHF18m in Series A financing to fund clinical trials for its lead compound VNA-318. The company is a spin out of Amazentis SA and focuses on the development of mitophagy inducers for the treatment of neurodegenerative diseases.
- Vandria SA has raised CHF18m in Series A financing led by ND Capital and a syndicate of high-net-worth private investors.
- The funding will be used to drive the clinical development of VNA-318, a mitophagy inducer that has demonstrated memory and learning improvement in preclinical models for CNS diseases such as Alzheimer’s and Parkinson’s.
- Vandria SA’s platform and pipeline are based on 15 years of discovery and clinical science, focusing on the selective removal and replacement of damaged mitochondria and anti-inflammatory effects.
- VNA-318 targets patients with early-stage CNS and neurodegenerative disorders to treat cognitive impairment and limit memory loss progression.
- Vandria SA sees economic potential in the global market for Alzheimer’s disease, which is estimated at US$7.6bn and expected to grow at a CAGR of 12% to 2035.
Conclusion:
Vandria SA has secured CHF18m in financing to support the clinical development of its lead compound VNA-318, which has shown promising results in preclinical models for CNS diseases. The funding will enable Vandria to conduct clinical trials and potentially address the unmet medical need in the treatment of cognitive impairment and neurodegenerative disorders. With its focus on mitophagy inducers, Vandria SA aims to make a significant impact in the field of neurodegenerative disease research and treatment.
